Hydrochlorothiazide And Olmesartan

Introduction Overview

Generic Name

hydrochlorothiazide and olmesartan

Brand Name

Benicar HCT

Dosage Form

oral tablet (12.5 mg-20 mg; 12.5 mg-40 mg; 25 mg-40 mg)

Drug Class

Angiotensin II inhibitors with thiazides

Pharmacokinetics

Absorption:
Hydrochlorothiazide and olmesartan are both administered orally and absorbed through the gastrointestinal tract with adequate bioavailability. Hydrochlorothiazide is absorbed primarily in the small intestine and reaches peak plasma concentration within 1 to 5 hours post-administration. Olmesartan medoxomil, a prodrug, is rapidly hydrolyzed to the active angiotensin receptor antagonist olmesartan during absorption in the gastrointestinal tract with peak plasma concentrations occurring approximately 1 to 2 hours after dosing. The absorption of olmesartan is approximately 26%, which is relatively low but sufficient to achieve effective plasma levels. Absorption may be influenced by food intake, but clinical studies indicate that food does not significantly affect the antihypertensive efficacy of the combination.

Distribution:
Hydrochlorothiazide demonstrates a volume of distribution between 4 to 8 L/kg, indicating moderate distribution throughout body tissues. It binds moderately to plasma proteins (40%) and penetrates body fluids including glomerular filtrate, which facilitates its diuretic action in the renal tubules. Olmesartan exhibits a volume of distribution of around 17 L, binding extensively to plasma proteins (approximately 99%), mainly to serum albumin and alpha-1 acid glycoprotein. This high plasma protein binding results in limited tissue distribution but sustained plasma concentrations. The combination of hydrochlorothiazide and olmesartan leads to additive pharmacodynamic effects without significant alteration in individual distribution profiles.

Metabolism:
Hydrochlorothiazide undergoes minimal hepatic metabolism; it is primarily excreted unchanged in the urine, indicating negligible biotransformation and limited involvement in hepatic enzyme pathways. Conversely, olmesartan medoxomil is rapidly hydrolyzed during absorption to olmesartan, the active metabolite, and thereafter undergoes limited further metabolism predominantly via conjugation to form inactive glucuronides. The metabolic pathways do not rely on cytochrome P450 enzymes significantly, consequently reducing potential metabolic drug-drug interactions.

Elimination:
Hydrochlorothiazide is eliminated predominantly by renal excretion of unchanged drug, with approximately 60-70% excreted via kidneys within 24 hours. The elimination half-life is approximately 6 to 15 hours, with duration of action lasting up to 12 hours. Olmesartan is eliminated via biliary and renal routes; around 40% of olmesartan is excreted unchanged through feces, and about 35-50% is excreted in urine. The plasma elimination half-life of olmesartan ranges from 10 to 15 hours, supporting once-daily dosing. Impairment of renal or hepatic function can alter elimination kinetics, necessitating dose adjustments or careful monitoring.

Dosage Forms

Available Dosage Forms:
Hydrochlorothiazide and olmesartan are available as oral tablets with specific fixed-dose combinations:
- 12.5 mg hydrochlorothiazide / 20 mg olmesartan
- 12.5 mg hydrochlorothiazide / 40 mg olmesartan
- 25 mg hydrochlorothiazide / 40 mg olmesartan

Dosages for Adults and Adolescents:
The usual adult dose for hypertension treatment is once daily administration of hydrochlorothiazide 12.5 to 25 mg combined with olmesartan 20 to 40 mg. Therapy often begins with monotherapy using either olmesartan or hydrochlorothiazide, and if blood pressure is inadequately controlled, the combination is initiated. Titration of doses can be performed every 2 to 4 weeks based on clinical response and tolerability. The maximal recommended doses are 40 mg olmesartan with 25 mg hydrochlorothiazide daily. Pediatric use is less established and typically requires specialist input.

Specific Patient Populations:
Careful consideration and dose adjustment may be required in patients with renal impairment to avoid volume depletion and electrolyte disturbances. In elderly patients, initial lower doses are recommended due to increased sensitivity to antihypertensives. Hepatic impairment may influence pharmacokinetics of olmesartan but usually does not necessitate dose adjustments. Use in pregnant women is contraindicated due to risks of fetal toxicity, especially in the second and third trimesters. The combination is also contraindicated in patients with anuria or hypersensitivity to either component. Regular monitoring of electrolyte levels, renal function, and blood pressure is essential in special populations.

Mechanism Of Action

Hydrochlorothiazide and olmesartan exert their antihypertensive effects through complementary but distinct pathways. Hydrochlorothiazide is a thiazide diuretic that acts primarily on the distal convoluted tubule of the nephron. It inhibits the sodium-chloride symporter, reducing sodium and chloride reabsorption, which increases sodium and water excretion. This diuretic action decreases plasma volume and consequently lowers blood pressure by reducing cardiac output and peripheral vascular resistance through sustained vasodilation.

Olmesartan is a selective angiotensin II receptor type 1 (AT1) antagonist. It competitively inhibits the binding of angiotensin II to the AT1 receptor found on vascular smooth muscle and other tissues. By blocking this receptor, olmesartan prevents angiotensin II–mediated vasoconstriction, aldosterone release, sodium retention, and sympathetic nervous system activation. This leads to vasodilation, decreased peripheral resistance, and lowered blood pressure.

The combination of hydrochlorothiazide and olmesartan provides additive antihypertensive effects because hydrochlorothiazide reduces plasma volume through diuresis, while olmesartan counteracts the renin-angiotensin-aldosterone system (RAAS), mitigating the compensatory sodium retention and vasoconstriction that might occur with diuretics alone. This complementary mechanism improves efficacy and may reduce the required dose of each agent, potentially decreasing side effects.

Clinical studies demonstrate that the combination effectively lowers systolic and diastolic blood pressure, providing sustained control in patients who are inadequately managed with monotherapy. Olmesartan’s blockade of the angiotensin II receptor also offers protective effects against cardiovascular and renal remodeling, which contributes to end-organ protection beyond blood pressure reduction.

Pharmacological Actions

Antihypertensive effect via combined diuretic and RAAS inhibition mechanisms
Increases renal sodium and water excretion through inhibition of sodium-chloride symporter by hydrochlorothiazide
Blocks angiotensin II AT1 receptors preventing vasoconstriction and aldosterone secretion
Reduces plasma volume and peripheral vascular resistance resulting in lower blood pressure
Mitigates compensatory RAAS activation associated with diuretic monotherapy
Exerts renoprotective effects by reducing glomerular hypertension and proteinuria
Decreases cardiac workload and oxygen demand through vasodilation
Improves vascular compliance and endothelial function
Potassium-wasting diuretic activity of hydrochlorothiazide is balanced by potassium-sparing effect of olmesartan
Reduces serum uric acid reabsorption leading to elevated uric acid levels (common side effect)
Exhibits a long duration of action supporting once daily dosing
Minimal metabolism and limited drug-drug interaction potential
Synergistic blood pressure lowering with low incidence of reflex tachycardia

Therapeutic Or Clinical Uses

Management of essential hypertension to reduce cardiovascular morbidity and mortality
Treatment of patients inadequately controlled with monotherapy of either hydrochlorothiazide or olmesartan
Adjunct therapy to achieve blood pressure targets in resistant hypertension
Alternative combination therapy for patients intolerant to ACE inhibitors
Prevention of stroke, myocardial infarction, and heart failure by effective blood pressure control
Potential renoprotective role in hypertensive patients with nephropathy
Used in patients at high risk of cardiovascular events needing combined RAAS blockade and diuresis
Management option when dual pathophysiological mechanisms contribute to hypertension
Guideline-recommended combination therapy in certain hypertensive populations
Treatment of hypertension concomitant with electrolyte imbalances requiring potassium modulation

Side Or Adverse Effects

Nausea and gastrointestinal discomfort
Dizziness and light-headedness especially on standing (orthostatic hypotension)
Upper respiratory symptoms such as stuffy nose, sneezing, and sore throat
Increased serum uric acid possibly leading to gout attacks
Electrolyte disturbances including hyponatremia, hypokalemia, and hyperkalemia
Muscle cramps, weakness, or fatigue related to electrolyte imbalance
Rare allergic reactions including rash, angioedema, or anaphylaxis
Elevated liver enzymes and rare cases of jaundice
Potential risk of kidney dysfunction or azotemia, especially in volume-depleted patients
Increased risk of photosensitivity and skin cancer with hydrochlorothiazide use
Headache and confusion secondary to electrolyte or blood pressure changes
Hyperglycemia as a possible effect of thiazide diuretics
Uncommon but serious rhabdomyolysis leading to kidney failure
Rare vision problems or eye pain possibly related to intraocular pressure changes
Bruising or bleeding abnormalities due to hematological changes

Precautions

Use with caution in patients with renal impairment to avoid worsening kidney function
Monitor electrolytes regularly to detect and manage hyponatremia, hypokalemia, or hyperkalemia
Avoid concurrent use with aliskiren in diabetic patients due to risk of adverse renal effects
Educate patients about orthostatic hypotension and advise to rise slowly from sitting or lying positions
Patients should avoid excessive alcohol consumption to prevent additive blood pressure lowering
Use sunscreen and protective clothing to reduce risk of photosensitivity and skin cancer
Inform patients about symptoms of electrolyte imbalance such as muscle weakness or irregular heartbeats
Monitor blood pressure regularly to assess therapeutic response and adjust dosage as needed
Consider potential drug interactions with NSAIDs, lithium, steroids, and other antihypertensive agents
Avoid use in pregnant or breastfeeding women due to fetal toxicity and drug excretion in milk
Use caution in patients with gout as hydrochlorothiazide may increase uric acid levels
Review patient history for allergies to sulfonamides or penicillin prior to initiation
Assess liver function in patients with hepatic impairment before prescribing
Ensure adequate hydration to reduce risk of hypotension and renal adverse effects
Counsel about the possibility of dizziness or impaired reaction time and avoid hazardous tasks initially

Warnings

Do not use if unable to urinate or in patients with anuria
Contraindicated in pregnancy due to risk of fetal injury or death especially in second and third trimesters
Risk of severe hypotension and acute renal failure in volume-depleted patients
Avoid concomitant use with aliskiren in patients with diabetes or renal impairment
Potential for electrolyte disturbances including dangerously low sodium or potassium levels
Risk of angioedema and severe allergic reactions requiring emergency attention
May cause dizziness or syncope, thus exercise caution when performing tasks requiring alertness
Increased risk of skin cancer associated with hydrochlorothiazide necessitates regular dermatologic evaluation
Use cautiously in patients with a history of gout due to hyperuricemia
Potential interactions with NSAIDs that may reduce antihypertensive efficacy and worsen renal function
Drug-induced liver injury possible; observe for signs such as jaundice or elevated liver enzymes
Avoid abrupt discontinuation to prevent rebound hypertension
Monitor for signs of muscle breakdown such as unexplained muscle pain or weakness
May increase blood glucose and lipid levels; monitor diabetic patients accordingly
Concomitant use with multiple antihypertensive agents requires close monitoring for additive hypotension

Contraindication

Hypersensitivity to hydrochlorothiazide, olmesartan, or any components of the formulation
Anuria or severe renal impairment with inability to produce urine
Pregnancy due to risk of fetal toxicity and death
Concomitant use with aliskiren in patients with diabetes mellitus
Known hypersensitivity to sulfonamide-derived drugs due to cross-reactivity with hydrochlorothiazide
Severe hepatic impairment or cholestasis (caution advised)
Individuals with a history of angioedema related to previous ARB or ACE inhibitor therapy
Volume depletion or dehydration states without proper correction prior to treatment
Severe hyperkalemia or electrolyte imbalances not corrected before initiation
Patients unable to comply with monitoring requirements for potassium and renal function
Use in breastfeeding mothers owing to potential harmful effects in nursing infants
Concomitant use with drugs that can significantly increase serum potassium without monitoring
Known sensitivity or allergy to any thiazide diuretics
Severe hypotension or hypovolemia not stabilized prior to therapy
In pediatric patients due to lack of established safety and efficacy

Drug Interactions

NSAIDs (e.g., ibuprofen, naproxen, celecoxib) may reduce antihypertensive effect and impair renal function
Potassium supplements or potassium-sparing diuretics increasing risk of hyperkalemia
Aliskiren use in diabetics or renal impairment may increase risk of adverse renal events
Lithium clearance reduced by hydrochlorothiazide, increasing risk of toxicity
Steroids may potentiate hypokalemia caused by hydrochlorothiazide
Other antihypertensive agents have additive hypotensive effects when combined
Cholestyramine and colestipol may reduce absorption if administered concomitantly; separate dosing by 4 hours
Oral antidiabetic agents and insulin may have reduced efficacy or altered glucose control
Drugs that impair renal function may exacerbate potential nephrotoxicity
Drugs metabolized via non-CYP pathways with potential for additive side effects
Agents causing QT prolongation may have increased arrhythmogenic risk under hypokalemia
Diuretics may decrease renal clearance of calcium affecting calcium levels
Concomitant use with NSAIDs may increase risk of acute kidney injury
Nondepolarizing neuromuscular blocking agents may have prolonged effects with diuretics
Potential additive dehydration and electrolyte imbalance when used with laxatives or emetics

Preparations Of The Drug

Oral tablets containing fixed-dose combinations of hydrochlorothiazide and olmesartan medoxomil
Available strengths include 12.5 mg hydrochlorothiazide/20 mg olmesartan, 12.5 mg/40 mg, and 25 mg/40 mg combinations
Tablets are film-coated for ease of swallowing and stability
Packaged in blister packs or bottles to protect from moisture and light
Supplied for once-daily oral administration without requirement for dose splitting
Produced following good manufacturing practices ensuring consistent drug content
Prescribed with specific titration regimens to optimize clinical response and minimize adverse effects
Storage instructions entail room temperature away from excess moisture and heat
Patient information leaflets are included to inform about administration, side effects, and precautions
Available through prescription-only access in most markets
Generic and brand name formulations are marketed internationally
Formulated to maintain stability and bioavailability through shelf life
Compatible with standard oral dosing devices; no injectable or alternative routes available
Packaging designed to reduce risk of accidental pediatric ingestion
Manufacturers provide professional prescribing information and patient support resources